Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

>2 years 11-15 visits Confirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines InjectionAllergologyDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Risankizumab

Risankizumab is a substance that blocks a specific immune signal to reduce skin inflammation in people with moderate to severe plaque psoriasis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

AbbV-066

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Thermalsole- Und Schwefelbad Bentheim GmbH

Klinik fuer Dermatologie und Allergologie

Bad Bentheim, Germany

Universitaetsklinikum Bonn AöR

AoeR Klinik und Poliklinik fuer Dermatologie und Allergologie

Bonn, Germany

Universitaetsklinikum Carl Gustav Carus An Der Technischen Universitaet Dresden AöR

Klinik und Poliklinik fuer Dermatologie

Dresden, Germany

Sponsor: Abbvie Deutschland GmbH & Co. KG

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.